News

Zacks Investment Research on MSN1h
FDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger Adults
GSK plc GSK announced that the FDA has accepted its regulatory filing seeking to expand the use of its RSV vaccine, Arexvy, in adults under 50 who are at a higher risk of the disease. A final decision ...
GSK eyes FDA label expansion for RSV vaccine Arexvy to include younger patients
GSK has applied to the US Food and Drug Administration (FDA) to extend use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults under the age of 50 who are at increased risk of the ...
GSK seeks FDA nod for expanded use of RSV vaccine in adults
If approved in the world's biggest pharmaceuticals market, GSK's vaccine, Arexvy, would be competing for a market share in ...
Warning for UK households getting common jab over risk of paralysing illness
As many as 20 people developed a potentially paralysing illness after getting the respiratory syncytial virus (RSV) vaccine.